SCHEMBL9933437

SCHEMBL9933437

O=C(O)N1C[C@@H]2C(c3nnc(C4CC4)o3)[C@@H]2C1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM5A P29375 1/20 0.38
EPHX2 P34913 2/20 0.33
ADCY1 Q08828 1/20 0.33
KMT2A Q03164 3/20 0.33
MAPT P10636 2/20 0.33
POLB P06746 1/20 0.33
ADRB3 P13945 1/20 0.32
KCNH2 Q12809 1/20 0.32
PDK2 Q15119 2/20 0.31
PDK1 Q15118 1/20 0.31
MEN1 O00255 2/20 0.31
HTT P42858 1/20 0.31
NPC1 O15118 1/20 0.31
HPGD P15428 1/20 0.31
ATM Q13315 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
GAA P10253 1/20 0.31
THRB P10828 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
HDAC3 O15379 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9933435 1.00 KDM5A (0.38) KDM5AEPHX2ADCY1KMT2AMAPT
SCHEMBL9932992 0.82 KDM5A (0.38) KDM5AADRB3KCNH2
SCHEMBL9932991 0.82 KDM5A (0.38) KDM5AADRB3KCNH2
SCHEMBL9934123 0.81 KDM5A (0.54) KDM5AADRB3KCNH2HSD11B1
SCHEMBL9934126 0.81 KDM5A (0.54) KDM5AADRB3KCNH2HSD11B1
SCHEMBL9934762 0.77 KDM5A (0.36) KDM5APDK2
SCHEMBL9934765 0.77 KDM5A (0.36) KDM5APDK2
SCHEMBL9933425 0.74 HCRTR1 (0.38) EPHX2HSD11B1
SCHEMBL9933427 0.74 HCRTR1 (0.38) EPHX2HSD11B1
SCHEMBL9934955 0.74 ADRB3 (0.35) KDM5AADRB3KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8354403-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2013-01-15 US disclosed
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME, CORP. (US) 2012-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 KDM5A 2967/4885EPHX2 2132/4885ADCY1 506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.